Clinical Trial Update: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis [Phase 2]

View source ↗

Summary

Phase 2 randomized trial evaluating subcutaneous AGX-201 for migraine prophylaxis; current status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Prophylaxis

Drugs mentioned

• AGX-201

Snippet

Sponsor: AgoneX Biopharmaceuticals, Inc. | Conditions: Migraine Prophylaxis | Phase 2 | Status: UNKNOWN